Stock DNA
Pharmaceuticals & Biotechnology
USD 26 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.30
-65.53%
4.28
Revenue and Profits:
Net Sales:
26 Million
(Quarterly Results - Jun 2025)
Net Profit:
-4 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-1.69%
0%
-1.69%
6 Months
-12.26%
0%
-12.26%
1 Year
3.56%
0%
3.56%
2 Years
8.77%
0%
8.77%
3 Years
-57.63%
0%
-57.63%
4 Years
-73.85%
0%
-73.85%
5 Years
-51.15%
0%
-51.15%
Mannatech, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-5.92%
EBIT Growth (5y)
-160.72%
EBIT to Interest (avg)
2.07
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.75
Sales to Capital Employed (avg)
9.50
Tax Ratio
92.70%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
22.35%
ROCE (avg)
103.76%
ROE (avg)
10.86%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.83
EV to EBIT
-23.33
EV to EBITDA
11.33
EV to Capital Employed
12.46
EV to Sales
0.20
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-33.39%
ROE (Latest)
-2.90%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bullish
No Trend
Shareholding Snapshot : Jun 2025
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 5 Schemes (5.62%)
Foreign Institutions
Held by 7 Foreign Institutions (0.28%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
25.70
26.60
-3.38%
Operating Profit (PBDIT) excl Other Income
-0.70
-0.10
-600.00%
Interest
0.10
0.10
Exceptional Items
0.00
0.00
Consolidate Net Profit
-4.30
-1.50
-186.67%
Operating Profit Margin (Excl OI)
-56.20%
-31.40%
-2.48%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is -3.38% vs -8.28% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -186.67% vs -165.22% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
117.90
132.00
-10.68%
Operating Profit (PBDIT) excl Other Income
3.00
2.60
15.38%
Interest
0.30
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
2.50
-2.20
213.64%
Operating Profit Margin (Excl OI)
12.10%
-7.30%
1.94%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -10.68% vs -3.79% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 213.64% vs 51.11% in Dec 2023
About Mannatech, Inc. 
Mannatech, Inc.
Pharmaceuticals & Biotechnology
Mannatech, Incorporated is a wellness solution provider. The Company develops and sells nutritional supplements, topical and skin care and anti-aging products, and weight-management products. The Company operates through the segment of sale of nutritional supplements, skin care and anti-aging products, and weight management and fitness products through network marketing distribution channels in approximately 20 countries. Its Health category includes a range of daily nutritional supplements, health solutions for children and additional nutrients designed to help keep specific body systems at optimal levels. Its Weight and Fitness category offers products designed to curb appetite and burn fat, build lean muscle tissue, and support recovery from overexertion. Its Skin Care and Anti-Aging category offers products formulated with approximately 30 botanical ingredients. It sells products in three regions: North America/South America, Europe/the Middle East/Africa (EMEA) and Asia/Pacific.
Company Coordinates 
Company Details
1410 Lakeside Pkwy Ste 200 , FLOWER MOUND TX : 75028-4099
Registrar Details






